Laboratory of Bioanalysis and Molecular Imaging, Faculty of Pharmaceutical Sciences, Hokkaido University.
Institute for Chemical Reaction Design and Discovery (ICReDD), Hokkaido University.
Biol Pharm Bull. 2024;47(6):1066-1071. doi: 10.1248/bpb.b24-00008.
Both nuclear and optical imaging are used for in vivo molecular imaging. Nuclear imaging displays superior quantitativity, and it permits imaging in deep tissues. Thus, this method is widely used clinically. Conversely, because of the low permeability of visible to near-IR light in living animals, it is difficult to visualize deep tissues via optical imaging. However, the light at these wavelengths has no ionizing effect, and it can be used without any restrictions in terms of location. Furthermore, optical signals can be controlled in vivo to accomplish target-specific imaging. Nuclear medicine and phototherapy have also evolved to permit targeted-specific imaging. In targeted nuclear therapy, beta emitters are conventionally used, but alpha emitters have received significant attention recently. Concerning phototherapy, photoimmunotherapy with near-IR light was approved in Japan in 2020. In this article, target-specific imaging and molecular targeted therapy utilizing nuclear medicine and optical technologies are discussed.
核医学成像和光学成像均可用于体内分子成像。核医学成像具有更高的定量能力，并且可以对深部组织进行成像。因此，该方法在临床上得到了广泛应用。相反，由于活体动物对可见光到近红外光的穿透率较低，通过光学成像很难对深部组织进行可视化。然而，这些波长的光没有电离作用，因此可以在不限制位置的情况下使用。此外，光学信号可以在体内进行控制，以实现靶向特异性成像。核医学和光疗也已经发展到可以进行靶向特异性成像。在靶向核治疗中，通常使用β发射器，但最近α发射器受到了广泛关注。关于光疗，近红外光的光免疫疗法已于 2020 年在日本获得批准。本文讨论了利用核医学和光学技术进行的靶向特异性成像和分子靶向治疗。
